Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lilly/BI Eye Diabetes Leadership In Expansive Risk-Sharing Collaboration

This article was originally published in The Pink Sheet Daily

Executive Summary

The two drug makers will jointly develop four diabetes drugs: two oral agents from Boehringer Ingelheim and two basal insulin analogues from Lilly.
Advertisement

Related Content

Lilly and Boehringer Ingelheim Launch Biosimilar Lantus In UK, Germany
Merck And Pfizer Make A Late Play For The Diabetes Market
Lilly Right-Sizes Sales Force As It Pushes Its Pipeline Forward
Lilly/BI Report Success For Oral Diabetes Drug, Adjust Alliance
Biosimilar Insulin Worth The Effort? For Some, Maybe
CHMP Positive On Trajenta, Vectibix, Votubia And Eurartesim, But Negative On Bronchitol, Luveniq And Glybera
Boehringer Enhances Diabetes Pipeline With Zealand's GLP-1/Glucagon Agonist
J.P. Morgan: News And Observations From Our Reporters’ Notebooks
Boehringer Ingelheim Plays Catch-Up In Diabetes, Close To Filing DPP-4 Drug
Boehringer Ingelheim Plays Catch-Up In Diabetes, Close To Filing DPP-4 Drug

Topics

Advertisement
UsernamePublicRestriction

Register

PS071682

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel